Merck & Co., Inc.
Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada
Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →
Key metrics · each point sourced
Stated objectives
Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial
sourceEvaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007
sourceEvaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007
sourceSubmit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results
sourceInitiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC
sourceFull-year sales forecast
sourceFull-year EPS forecast
sourceImproving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies
sourceBecome the premier research-intensive biopharmaceutical company in the world
sourceDeliver innovative health solutions that advance the prevention and treatment of diseases in people and animals
source